NKTR
Nektar Therapeutics
60.50$
+2.2%
vs. previous close
Closing price · As of: Sep 30, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -70.8% | -31.7% | -70.7% | -26.1% | 60.2% | -286.8% | -204.9% | -404.9% | -330.2% | -213.7% | -178.5% | -377.5% | |
| 6.4% | 5.6% | 9.3% | 4.8% | 0.9% | 11.5% | 9.3% | 13.9% | 14.2% | 8.7% | 4.5% | -8.1% | |
| 8.5% | 8.5% | 15.6% | 11.9% | 7.4% | 87.1% | 61.6% | 92.9% | 62.3% | 37.0% | 22.0% | 22.9% | |
| 7.7% | 7.6% | 8.0% | 7.8% | 6.4% | 77.2% | 49.7% | 117.9% | 55.0% | – | – | – | |
| -58.0% | -15.0% | 4.8% | -12.2% | -3.3% | 18.9% | 10.9% | -22.6% | 0.5% | -22.0% | -6.3% | -67.0% | |
| 5.0% | 4.9% | 3.9% | 3.1% | 1.2% | 22.9% | 4.7% | 14.7% | 6.2% | 1.0% | 1.5% | 0.3% | |
| -18.7% | -6.2% | -49.8% | -9.4% | -115.6% | 180.5% | 324.5% | 199.0% | 397.4% | 154.9% | 144.8% | -2.2% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 81.5% | 14.0% | 126.7% | 19.3% | 71.4% | 20.4% | 15.3% | 32.6% | – | 0.0% | -3.0% | 0.0% | |
| -1.8% | 42.7% | -3.6% | -1.7% | -20.9% | -218.1% | -163.5% | 0.0% | 0.0% | – | – | – | |
| 76.2% | 56.7% | 123.1% | 17.7% | 71.4% | 20.4% | -52.5% | 35.6% | 1.6% | 0.0% | 42.8% | 326.9% | |
| -13.3% | 18.7% | 2.5% | -17.8% | 15.9% | -86.0% | 67.1% | -170.5% | 68.4% | -58.8% | 9.1% | -52.8% | |
| -75.7% | -36.5% | -74.6% | -29.3% | 59.0% | -309.7% | -209.6% | -419.6% | -336.4% | -214.7% | -180.0% | -377.8% |
Data as of: September 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.